Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2000(2):CD000212.
doi: 10.1002/14651858.CD000212.

Interventions for psoriatic arthritis

G Jones  1 , M Crotty, P Brooks
Affiliations

Interventions for psoriatic arthritis

G Jones et al. Cochrane Database Syst Rev. 2000.

Update in

  • Interventions for psoriatic arthritis.
    Jones G, Crotty M, Brooks P. Jones G, et al. Cochrane Database Syst Rev. 2000;(3):CD000212. doi: 10.1002/14651858.CD000212. Cochrane Database Syst Rev. 2000. PMID: 10908464

Abstract

Objectives: To assess the effects of salazopyrin, auranofin, etretinate, fumaric acid, IMI gold, azathioprine, and methotrexate, in psoriatic arthritis.

Search strategy: We searched Medline up to 1995, and Excerpta Medica (June 1974-95). Search terms were psoriasis, arthritis, therapy and/or controlled trial. This was supplemented by manually searching bibliographies of previously published reviews, conference proceedings and contacting drug companies. All languages were included in the initial search.

Selection criteria: All randomized trials comparing salazopyrin, auranofin, etretinate, fumaric acid, IMI gold, azathioprine, and methotrexate, in psoriatic arthritis. The main outcome measures included individual component variables derived from Outcome Measures in Rheumatology Clinical Trials (OMERACT). These include Acute Phase Reactants, Disability, Pain, Patient Global Assessment, Physician Global Assessment, Swollen joint count, Tender joint count and radiographic changes of joints in any trial of 1 year or longer [Tugwell 1993], and the change in pooled disease index. Only English trials were included in the review.

Data collection and analysis: Data were independently extracted from the published reports by two of the reviewers. An independent blinded quality assessment was also performed.

Main results: Nineteen randomized trials were identified of which eleven were included in the quantitative analysis with data from 777 subjects. Although all agents were better than placebo, parenteral high dose methotrexate (not included), salazopyrin, azathioprine and etretinate were the agents that achieved statistical significance in a global index of disease activity (although it should be noted that only one component variable was available for azathioprine and only one trial was available for etretinate suggesting some caution is necessary in interpreting these results). Analysis of response in individual disease activity markers was more variable with considerable differences between different medications and responses. In all trials the placebo group improved over baseline (pooled improvement 0.43 DI units, 95% CI 0. 28-0.59). There was insufficient data to examine toxicity.

Reviewer's conclusions: Parenteral high dose methotrexate and salazopyrin are the only two agents with well demonstrated published efficacy in psoriatic arthritis. The magnitude of the effect seen with azathioprine, etretinate, oral low dose methotrexate and perhaps colchicine suggests that they may be effective but that further multicentre clinical trials are required to establish their efficacy. Furthermore, the magnitude of the improvement observed in the placebo group strongly suggests that uncontrolled trials should not be used to guide management decisions in this condition.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1.1
1.1. Analysis
Comparison 1 Treatment versus placebo, Outcome 1 Pooled disease index.
1.2
1.2. Analysis
Comparison 1 Treatment versus placebo, Outcome 2 Pain (VAS).
1.3
1.3. Analysis
Comparison 1 Treatment versus placebo, Outcome 3 ESR (mm/hr).
1.4
1.4. Analysis
Comparison 1 Treatment versus placebo, Outcome 4 Tender joint score (Ritchie Index).
1.5
1.5. Analysis
Comparison 1 Treatment versus placebo, Outcome 5 Swollen joint score.
1.6
1.6. Analysis
Comparison 1 Treatment versus placebo, Outcome 6 Patient global assessment.
1.7
1.7. Analysis
Comparison 1 Treatment versus placebo, Outcome 7 Physician global assessment.
See this image and copyright information in PMC

References

References to studies included in this review

Carette 1989 {published data only}
    1. Carette S, Calin A, McCafferty JP, Wallin BA and the Auranofin Cooperating Group. A double‐blind placebo controlled trial of auranofin in psoriatic arthritis. Arthritis and Rheumatism 1989;32:158‐65. - PubMed
Clegg 1996 {published data only}
    1. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulphasalzine and placebo for the treatment of psoriatic arthritis and cutaneous psoriasis. Arthritis and Rheumatism 1996;39:2013‐20. - PubMed
Combe 1996 {published and unpublished data}
    1. Combe B, Goupille P, Kuntz JL, et al. Sulphasalazine in psoriatic arthritis: a randomised multicentre placebo‐controlled study. British Journal of Rheumatology 1996;35:664‐8. - PubMed
Dougados 1995 {published and unpublished data}
    1. Dougados M, Linden S, Leirisalo‐Repo M. Sulphasalazine in the treatment of spondyloarthropathy: a randomised multicentre double‐blind placebo controlled study. Arthritis and Rheumatism 1995;38:618‐27. - PubMed
Farr 1990 {published and unpublished data}
    1. Farr M, Kitas GD, Waterhouse L, et al. Suplhasalazine in psoriatic arthritis: a double‐blind placebo‐controlled study. British Journal of Rheumatology 1990;29:46‐9. - PubMed
Fraser 1993 {published and unpublished data}
    1. Fraser SM, Hopkins R, Hunter JA, Neumann V, Capell HA, Bird HA. Sulphasalazine in the management of psoriatic arthritis. British Journal of Rheumatology 1993;32:923‐5. - PubMed
Gupta 1995 {published data only}
    1. Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine therapy for psoriatic arthritis: a double‐blind, placebo controlled trial. Journal of Rheumatology 1995;22:894‐8. - PubMed
Hopkins 1985 {published data only}
    1. Hopkins R, Bird HA, Jones H, Hill J, Surrall KE, Astbury, et al. A double‐blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis. Annals of the Rheumatic Diseases 1985;44:189‐93. - PMC - PubMed
Levy 1972 {published data only}
    1. Levy J, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM. A double‐blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis and Rheumatism 1972;15:116‐7.
McKendry 1993 {published and unpublished data}
    1. McKendry RJR, Kraag G, Seigel S, Awadhi AA. Therapeutic value of colchicine in the treatment of patients with psoriatic arthritis. Annals of the Rheumatic Diseases 1993;52:826‐8. - PMC - PubMed
Palit 1990 {published and unpublished data}
    1. Palit J, Hill J, Capell HA, et al. A multicentre double‐blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. British Journal of Rheumatology 1990;29:280‐3. - PubMed
Peeters 1992 {published data only}
    1. Peeters AJ, Dijkmans BA, Scroeff JG. Fumaric acid therapy for psoriatic arthritis. A randomised double‐blind placebo‐controlled study (letter). British Journal of Rheumatology 1992;31(7):502‐4. - PubMed
Willkens 1984 {published and unpublished data}
    1. Willkens RE, Williams J, Ward JR, et al. Randomized, double‐blind, placebo controlled trial of low‐dose pulse methotrexate in psoriatic arthritis. Arthritis and Rheumatism 1984;27(4):376‐81. - PubMed

References to studies excluded from this review

Black 1964 {published data only}
    1. Black RL, O'Brien WM, Scott EJ, et al. Methotrexate therapy in psoriatic arthritis. JAMA 1964;189:743‐7. - PubMed
Bruckle 1994 {published data only}
    1. Bruckle W, Dexel T, Grasedyck K, Schattenkirchner M. Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clinical Rheumatology 1994;13:209‐16. - PubMed
Caperton 1990 {published data only}
    1. Caperton EM, Heim‐Duthoy KL, Matzke GR. Ceftriaxone therapy of chronic inflammatory arthritis, A double‐blind placebo controlled trial. Archives of Internal Medicine 1990;150:1677‐82. - PubMed
Fierlbeck 1990 {published data only}
    1. Fierlbeck G, Rassner G. Treatment of psoriasis and psoriatic arthritis with interferon gamma. Journal of Investigative Dermatology 1990;95:138‐41S. - PubMed
Price 1986 {published data only}
    1. Price R, Gibson T. D‐Penicillamine and psoriatic arthropathy. British Journal of Rheumatology 1986;24:228. - PubMed
Seideman 1987 {published data only}
    1. Seideman P, Fjellner B, Johanesson L. Psoriatic arthritis treated with oral colchicine. Journal of Rheumatology 1987;14:777‐9. - PubMed
Veale 1994 {published data only}
    1. Veale DJ, Torley HI, Richards IM, O'Dowd, A, Fitzsimons C, Belch JJF, Sturrock RD. A double‐blind placebo controlled trial of efamol marine on skin and joint symptoms of psoriatic arthritis. British Journal of Rheumatology 1994;33:954‐8. - PubMed

Additional references

Dorwart 1978
    1. Dorwart BB, Gall EP, Schumacher HR, Krauser RE. Chrysotherapy in psoriatic arthritis: efficacy and toxicity compared to rheumatoid arthritis. Arthritis and Rheumatism 1978;21:513‐5. - PubMed
Felson 1990
    1. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second‐line drugs in rheumatoid arthritis. Arthritis and Rheumatism 1990;33:1449‐61. - PubMed
Gladman 1990
    1. Gladman DD, Stafford‐Brady F, Chang CH, Lewandowksi K, Russell MC. Longterm study of clinical and radiological progression in psoriatic arthritis. Journal of Rheumatology 1990;17:809‐12. - PubMed
Goldsmith 1993
    1. Goldsmith CH, Smythe HA, Helewa A. Interpretation and power of a pooled index. Journal of Rheumatology 1993;20:575‐8. - PubMed
Leonard 1978
    1. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalised for psoriasis. Mayo Clinic Proceedings 1978;53:511‐8. - PubMed
Roberts 1976
    1. Roberts MCT, Wright V, Hill AGS, Mehra AC. Psoriatic arthritis: a follow‐up study. Annals of the Rheumatic Diseases 1976;35:206‐12. - PMC - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12. - PubMed
Tugwell 1993
    1. Tugwell P, Boers M. OMERACT Conference on outcome measures in rheumatoid arthritis clinical trials: conclusion. Journal of Rheumatology 1993;20:590. - PubMed
Wilson 1992
    1. Wilson A, Henry DA. Meta‐analysis. Part 2: Assessing the quality of published meta‐analyses. Medical Journal of Australia 1992;156:173‐87. - PubMed
Wright 1976
    1. Wright V, Moll MH. Seronegative polyarthritis. Amsterdam: North Holland Publishing Company, 1976.

Publication types

MeSH terms